Human CD44+/CD23-low breast CSCs were found to undergo apoptosis after 2-DG treatment and exhibited higher sensitivity to doxorubicin, a chemotherapy agent serving as the backbone of breast cancer therapeutics [80]. The gene discussed is CD44; the disease is breast carcinoma.